Ma X.
2018.
Sensing danger through a "finger".. J Exp Med. 215(12):2969-2971.
Mansfield CR, Quan B, Chirgwin ME, Eduful B, Hughes PF, Neveu G, Sylvester K, Ryan DH, Kafsack BFC, Haystead TAJ et al..
2024.
Selective targeting of Plasmodium falciparum Hsp90 disrupts the 26S proteasome.. Cell Chem Biol. 31(4):729-742.e13.
Zhan W, Hsu H-C, Morgan T, Ouellette T, Burns-Huang K, Hara R, Wright AG, Imaeda T, Okamoto R, Sato K et al..
2019.
Selective Phenylimidazole-Based Inhibitors of the Mycobacterium tuberculosis Proteasome.. J Med Chem. 62(20):9246-9253.
Zhan W, Hsu H-C, Morgan T, Ouellette T, Burns-Huang K, Hara R, Wright AG, Imaeda T, Okamoto R, Sato K et al..
2019.
Selective Phenylimidazole-Based Inhibitors of the Mycobacterium tuberculosis Proteasome.. J Med Chem. 62(20):9246-9253.
Zhan W, Hsu H-C, Morgan T, Ouellette T, Burns-Huang K, Hara R, Wright AG, Imaeda T, Okamoto R, Sato K et al..
2019.
Selective Phenylimidazole-Based Inhibitors of the Mycobacterium tuberculosis Proteasome.. J Med Chem. 62(20):9246-9253.
Florini F, Visone JE, Hadjimichael E, Malpotra S, Nötzel C, Kafsack BFC, Deitsch KW.
2025.
scRNA-seq reveals transcriptional plasticity of var gene expression in Plasmodium falciparum for host immune avoidance.. Nat Microbiol. 10(6):1417-1430.
Blumenthal A, Kobayashi T, Pierini LM, Banaei N, Ernst JD, Miyake K, Ehrt S.
2009.
RP105 facilitates macrophage activation by Mycobacterium tuberculosis lipoproteins.. Cell Host Microbe. 5(1):35-46.
Yamamoto S, Ma X.
2009.
Role of Nod2 in the development of Crohn's disease.. Microbes Infect. 11(12):912-8.
Saito K, Warrier T, Somersan-Karakaya S, Kaminski L, Mi J, Jiang X, Park S, Shigyo K, Gold B, Roberts J et al..
2017.
Rifamycin action on RNA polymerase in antibiotic-tolerant Mycobacterium tuberculosis results in differentially detectable populations.. Proc Natl Acad Sci U S A. 114(24):E4832-E4840.
Chen X, Lee SKoo, Song M, Zhang T, Han MShin, Chen Y-T, Chen Z, Ma X, Tung C-H, Du Y-CNancy.
2021.
RHAMMB-mediated bifunctional nanotherapy targeting Bcl-xL and mitochondria for pancreatic neuroendocrine tumor treatment.. Mol Ther Oncolytics. 23:277-287.
Anastassopoulou CG, Ketas TJ, Klasse PJohan, Moore JP.
2009.
Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41.. Proc Natl Acad Sci U S A. 106(13):5318-23.